×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
URGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/6
08:11 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
12/6
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/5
03:33 pm
urgn
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
Low
Report
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
12/5
03:30 pm
urgn
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Low
Report
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
12/5
03:15 pm
urgn
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Low
Report
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
12/2
07:59 pm
urgn
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade [Yahoo! Finance]
Medium
Report
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade [Yahoo! Finance]
12/2
08:19 am
urgn
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs [Yahoo! Finance]
Low
Report
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs [Yahoo! Finance]
12/2
08:00 am
urgn
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Low
Report
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
BEAT
Report
-1.6%
urogen pharma ltd. - ordinary shares
8/13/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
3.1%
urogen pharma ltd. - ordinary shares
5/13/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
2.6%
urogen pharma ltd. - ordinary shares
3/14/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
-18.0%
urogen pharma ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
06:16 am
urgn
Form SC 13D/A UroGen Pharma Ltd. Filed by: Pontifax Management III G.P. (2011) Ltd.
Low
Report
Form SC 13D/A UroGen Pharma Ltd. Filed by: Pontifax Management III G.P. (2011) Ltd.
11/14
07:46 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: Point72 Asset Management, L.P.
11/14
05:47 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
04:47 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: GREAT POINT PARTNERS LLC
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: GREAT POINT PARTNERS LLC
11/14
12:05 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: MENORA MIVTACHIM HOLDINGS LTD.
Low
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: MENORA MIVTACHIM HOLDINGS LTD.
11/14
08:37 am
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
Neutral
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
11/14
06:45 am
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: RTW INVESTMENTS, LP
Neutral
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: RTW INVESTMENTS, LP
11/12
09:35 am
urgn
Form SC 13G UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
Low
Report
Form SC 13G UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K UroGen Pharma Ltd. For: Mar 20
18.6%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
TOP News Decliners
9/24
Form 8-K UroGen Pharma Ltd. For: Sep 24
-19.9%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: